PACTR202108851511956Not yet recruitingPhase 1
Safety and feasibility of a malaria transmission model in semi-immune Kenyan adults using Plasmodium falciparum sporozoites
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- niversity of Oxford
- Enrollment
- 44
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 13 Year(s) to 18 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Healthy adults aged 18 to 45 years.
- •Able and willing (in the Investigator’s opinion) to comply with all study requirements.
- •Informed consent.
- •Use of effective method of contraception for duration of study (women only). We will ask the female volunteers to come with their family planning records to verify. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly, in accordance with the product label. Examples of these include: combined oral contraceptives; injectable progestogen; implants of etenogestrel or levonorgestrel; intrauterine device or intrauterine system; male partner sterilisation at least 6 months prior to the female subject’s entry into the study, and the relationship is monogamous; male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository); and male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).
Exclusion Criteria
- •Body weight of less than 50kg or body mass index (BMI) less than 18 or greater than 25 kg/m2 at screening.
- •Use of systemic antibiotics with known antimalarial activity within 30 days of administration of PfSPZ Challenge (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones and azithromycin).
- •Receipt of an investigational product in the 30 days preceding enrolment, or planned receipt during the study period.
- •Current participation in another clinical trial or recent participation within 12 weeks of enrolment.
- •Prior receipt of an investigational malaria vaccine.
- •Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed). This will also include Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) positivity.
- •Use of immunoglobulins or blood products within 3 months prior to enrolment.
- •Any serious medical condition reported or identified during screening that increases the risk of CHMI.
- •Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.
- •Women only; pregnancy, or an intention to become pregnant during the duration of the study.
- •Sickle cell trait or disease.
- •History of drug or alcohol abuse.
- •Known hypersensitivity to or contraindications for use of artemether-lumefantrine, chloroquine, piperaquine, primaquine, sulfadoxine-pyrimethamine, or history of severe (allergic) reactions to mosquito bites.
- •Confirmed gametocyte positivity at screening and/or a day before challenge
- •Confirmed parasite positive by PCR a day before challenge i.e. at C-1.
Investigators
Similar Trials
Suspended
Phase 1
Controlled Human Malaria Infection Transmission Model - Phase AMalaria,FalciparumNCT04280692University of Oxford44
Withdrawn
Phase 1
A Safety and Tolerability Study in healthy adult males for Tafuramycin-A attenuated Plasmodium falciparum NF54 blood stage parasites.MalariaACTRN12613000618752Griffith University6
Completed
Phase 1
Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and MaliMalariaNCT02334462National Institute of Allergy and Infectious Diseases (NIAID)538
Completed
Phase 4
Vivax Elimination With Tafenoquine (VET) StudyMalaria, VivaxPlasmodium VivaxPlasmodium Vivax MalariaMalariaNCT06575647Shoklo Malaria Research Unit1,242
Completed
Not Applicable
Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in MaliMalariaNCT02206451National Institute of Allergy and Infectious Diseases (NIAID)87